Production of functional chimaeric mouse/human antibody
- PMID: 6095115
- DOI: 10.1038/312643a0
Production of functional chimaeric mouse/human antibody
Abstract
The availability of monoclonal antibodies has revived interest in immunotherapy. The ability to influence an individual's immune state by administering immunoglobulin of the appropriate specificity may provide a powerful approach to disease control and prevention. Compared with immunoglobulin from other species, human immunoglobulin (Ig) might be best for such therapeutic intervention; it might function better with the recipient's effector cells and should itself be less immunogenic. The success of the mouse hybridoma system suggests that immunoglobulin of virtually any specificity can be obtained from a properly immunized animal. In the human system, however, immunization protocols are restricted by ethical considerations, and it is not yet clear whether human antibody-producing cell lines of the required specificity can be obtained from adventitiously immunized individuals or from in vitro immunized cells. A method which might circumvent these difficulties is to produce antibodies consisting of mouse variable regions joined to human constant regions. Therefore, we have constructed immunoglobulin genes in which the DNA segments encoding mouse variable regions specific for the hapten trinitrophenyl (TNP) are joined to segments encoding human mu and kappa constant regions. These 'chimaeric' genes are expressed as functional TNP-binding chimaeric IgM. We report here some of the properties of this novel IgM.
Similar articles
-
Expression of a VHC kappa chimaeric protein in mouse myeloma cells.Nature. 1984 May 24-30;309(5966):364-7. doi: 10.1038/309364a0. Nature. 1984. PMID: 6328310
-
Functional immunoglobulin M production after transfection of cloned immunoglobulin heavy and light chain genes into lymphoid cells.Proc Natl Acad Sci U S A. 1983 Oct;80(20):6351-5. doi: 10.1073/pnas.80.20.6351. Proc Natl Acad Sci U S A. 1983. PMID: 6312453 Free PMC article.
-
Production and functional characterization of two mouse/human chimeric antibodies with specificity for the tumor-associated Tn-antigen.Hybridoma. 2000 Jun;19(3):229-39. doi: 10.1089/02724570050109620. Hybridoma. 2000. PMID: 10952411
-
Variable region sequences of murine IgM anti-IgG monoclonal autoantibodies (rheumatoid factors). A structural explanation for the high frequency of IgM anti-IgG B cells.J Exp Med. 1986 Aug 1;164(2):407-27. doi: 10.1084/jem.164.2.407. J Exp Med. 1986. PMID: 3088205 Free PMC article.
-
Chimeric antibody: potential applications for drug delivery and immunotherapy.Biotherapy. 1991;3(1):43-53. doi: 10.1007/BF02175098. Biotherapy. 1991. PMID: 2009213 Review.
Cited by
-
Cancer nanomedicines: so many papers and so few drugs!Adv Drug Deliv Rev. 2013 Jan;65(1):80-8. doi: 10.1016/j.addr.2012.09.038. Epub 2012 Oct 1. Adv Drug Deliv Rev. 2013. PMID: 23036224 Free PMC article. Review.
-
Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids.Cancer Immunol Immunother. 1987;24(2):127-32. doi: 10.1007/BF00205589. Cancer Immunol Immunother. 1987. PMID: 3829046 Free PMC article.
-
Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for pancreatic cancer.Jpn J Cancer Res. 2000 Aug;91(8):817-24. doi: 10.1111/j.1349-7006.2000.tb01019.x. Jpn J Cancer Res. 2000. PMID: 10965023 Free PMC article.
-
A humanized antibody that binds to the interleukin 2 receptor.Proc Natl Acad Sci U S A. 1989 Dec;86(24):10029-33. doi: 10.1073/pnas.86.24.10029. Proc Natl Acad Sci U S A. 1989. PMID: 2513570 Free PMC article.
-
Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?MAbs. 2009 Jan-Feb;1(1):12-25. doi: 10.4161/mabs.1.1.7347. MAbs. 2009. PMID: 20046569 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials